Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654642 | 0.81 | CYP1A2 (1.00) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL11188983 | 0.81 | CYP2D6 (0.66) | CYP2D6CYP1A2CYP3A4PRMT1TP53 | |
| SCHEMBL5680420 | 0.79 | CYP2D6 (0.63) | CYP2D6CYP1A2CYP3A4PRMT1TP53 | |
| SCHEMBL14382767 | 0.79 | POLB (0.57) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| Hydrochloric Acid SCHEMBL6899318 | 0.79 | CYP1A2 (0.96) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL18272090 | 0.78 | CYP2D6 (0.61) | CYP2D6CYP1A2CYP3A4PRMT1TP53 | |
| SCHEMBL7796812 | 0.78 | CYP2D6 (0.61) | CYP2D6CYP1A2CYP3A4PRMT1SLC6A2 | |
| SCHEMBL10920937 | 0.77 | CYP2D6 (0.55) | CYP2D6CYP1A2CYP3A4PRMT1TP53 | |
| SCHEMBL6431176 | 0.76 | CYP3A4 (0.59) | CYP2D6CYP1A2CYP3A4PRMT1RIPK1 | |
| SCHEMBL9800583 | 0.76 | CYP2D6 (0.59) | CYP2D6CYP1A2CYP3A4PRMT1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9096525-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096525-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8513286-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513286-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2012146125-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-7396814-B2 | Metallopeptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | CD14, MYADM, MPO | CYP2D6 54/4885CYP1A2 194/4885CYP3A4 139/4885 |
| US-10865208-B2 | ATG7 inhibitors and the uses thereof | ATG7, BECN1, SQSTM1 | CYP2D6 1295/4885CYP1A2 1833/4885CYP3A4 2100/4885 |
| US-20140335201-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | CYP2D6 49/4885CYP1A2 4/4885CYP3A4 16/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CYP2D6 202/4885CYP1A2 111/4885CYP3A4 117/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | CYP2D6 49/4885CYP1A2 4/4885CYP3A4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.